Safety and immunogenicity of co-administered MF59-adjuvanted 2009 pandemic and plain 2009-10 seasonal influenza vaccines in rheumatoid arthritis patients on biologicals.

摘要: Summary Rheumatoid arthritis (RA) patients under immunosuppressive therapy are particularly susceptible to infections, mainly of the respiratory tract, thus vaccination may represent a strategy reduce their incidence in this vulnerable population. In 2009–10 influenza season, safety and immunogenicity co-administered non-adjuvanted seasonal MF59-adjuvanted pandemic vaccines were evaluated study 30 RA with anti-tumour necrosis factor (TNF)-α agents or Abatacept 13 healthy controls (HC). Patients HC underwent clinical laboratory evaluation before (T0), 1 (T1) 6 months (T2) after vaccinations. No severe adverse reactions, but significant increase total mild side effects versus HC observed. Both fulfilled three criteria Committee for Proprietary Medicinal Products (CPMP). Seroconversion rate any viral strain was, respectively, 68 versus 45 H1-A/Brisbane/59/07, 72 81 H3-A/Brisbane/10/07, 54 B/Brisbane/60/08 A/California/7/2009. A slight activated interferon (IFN)-γ-, TNF-α- interleukin (IL)-17A-secreting T cells at T1 compared T0, followed by reduction T2 both HC, was registered. conclusion, simultaneous administration adjuvanted is safe highly immunogenic. The largely overlapping results between terms antibody response cytokine-producing cells, further evidence vaccine on biologicals.